Works matching AU Parekh, Trilok

Results: 11

Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Published in:

2019

By:

Patel, Shreyaskumar;
von Mehren, Margaret;
Reed, Damon R.;
Kaiser, Pamela;
Charlson, John;
Ryan, Christopher W.;
Rushing, Daniel;
Livingston, Michael;
Singh, Arun;
Seth, Rahul;
Forscher, Charles;
D'Amato, Gina;
Chawla, Sant P.;
McCarthy, Sharon;
Wang, George;
Parekh, Trilok;
Knoblauch, Roland;
Hensley, Martee L.;
Maki, Robert G.;
Demetri, George D.

Publication type:

journal article

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

Published in:

2016

By:

Orlowski, Robert Z.;
Nagler, Arnon;
Sonneveld, Pieter;
Bladé, Joan;
Hajek, Roman;
Spencer, Andrew;
Robak, Tadeusz;
Dmoszynska, Anna;
Horvath, Noemi;
Spicka, Ivan;
Sutherland, Heather J.;
Suvorov, Alexander N.;
Xiu, Liang;
Cakana, Andrew;
Parekh, Trilok;
San‐Miguel, Jesús F.

Publication type:

journal article

The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer<sup>1</sup>.

Published in:

Applied Physiology, Nutrition & Metabolism, 2014, v. 39, n. 6, p. 693, doi. 10.1139/apnm-2013-0403

By:

Prado, Carla M.M.;
Baracos, Vickie E.;
Xiao, Jingjie;
Birdsell, Laura;
Stuyckens, Kim;
Park, Youn Choi;
Parekh, Trilok;
Sawyer, Michael B.

Publication type:

Article

Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2025, v. 25, n. 2, p. 124, doi. 10.1016/j.clml.2024.08.003

By:

Jing Christine Ye;
Biran, Noa;
Nair, Sandhya;
Xiwu Lin;
Keqin Qi;
Londhe, Anil;
Ammann, Eric;
Renaud, Thomas;
Kane, Colleen;
Parekh, Trilok;
Gray, Kathleen;
Peterson, Steve;
Costa, Luciano J.

Publication type:

Article

Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 385, doi. 10.1016/j.clml.2023.02.006

By:

Mateos, María-Victoria;
Chari, Ajai;
Usmani, Saad Z.;
Goldschmidt, Hartmut;
Weisel, Katja;
Qi, Keqin;
Londhe, Anil;
Nair, Sandhya;
Lin, Xiwu;
Pei, Lixia;
Ammann, Eric;
Kobos, Rachel;
Smit, Jennifer;
Parekh, Trilok;
Marshall, Alexander;
Slavcev, Mary;
Moreau, Philippe

Publication type:

Article

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 1047, doi. 10.1007/s00280-015-2705-z

By:

Mehren, Margaret;
Bookman, Michael;
Meropol, Neal;
Weiner, Louis;
Sherman, Eric;
Li, Jinhui;
Knoblauch, Roland;
Parekh, Trilok;
Cohen, Roger

Publication type:

Article

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.

Published in:

Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 4, p. 729, doi. 10.1007/s00280-014-2554-1

By:

Machiels, Jean-Pascal;
Staddon, Arthur;
Herremans, Catherine;
Keung, Chi;
Bernard, Apexa;
Phelps, Charles;
Khokhar, Nushmia;
Knoblauch, Roland;
Parekh, Trilok;
Dirix, Luc;
Sharma, Sunil

Publication type:

Article

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 5, p. 1223, doi. 10.1007/s00280-011-1614-z

By:

Lebedinsky, Claudia;
Gómez, Javier;
Park, Youn;
Nieto, Antonio;
Soto-Matos, Arturo;
Parekh, Trilok;
Alfaro, Vicente;
Roy, Elena;
Lardelli, Pilar;
Kahatt, Carmen

Publication type:

Article

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.

Published in:

Investigational New Drugs, 2018, v. 36, n. 3, p. 476, doi. 10.1007/s10637-017-0546-9

By:

Calvo, Emiliano;
Azaro, Analia;
Rodon, Jordi;
Dirix, Luc;
Huizing, Manon;
Senecal, Francis Mark;
LoRusso, Patricia;
Yee, Lorrin;
Poggesi, Italo;
de Jong, Jan;
Triantos, Spyros;
Park, Youn C.;
Knoblauch, Roland E.;
Parekh, Trilok V.;
Demetri, George D.;
von Mehren, Margaret

Publication type:

Article

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.

Published in:

Medical Oncology, 2013, v. 30, n. 1, p. 1, doi. 10.1007/s12032-012-0435-1

By:

Campo, José;
Sessa, Cristiana;
Krasner, Carolyn;
Vermorken, Jan;
Colombo, Nicoletta;
Kaye, Stan;
Gore, Martin;
Zintl, Patrik;
Gómez, Javier;
Parekh, Trilok;
Park, Youn;
McMeekin, Scott

Publication type:

Article

DIFFERENTIAL EXPRESSION OF TRANSFORMING GROWTH FACTOR-β TYPE I AND II RECEPTORS BY PULMONARY CELLS IN BLEOMYCIN-INDUCED LUNG INJURY: CORRELATION WITH REPAIR AND FIBROSIS.

Published in:

Experimental Lung Research, 2002, v. 28, n. 3, p. 233, doi. 10.1080/019021402753570527

By:

Khalil, Nasreen;
Parekh, Trilok V.;
O'Connor, Robert N.;
Gold, Leslie I.

Publication type:

Article